{"filings":[{"id":77724,"accession_number":"0001410098-26-000020","cik":1410098,"company_name":"CorMedix Inc.","ticker":"CRMD","form_type":"8-K","filed_at":"2026-05-14T11:34:46+00:00","items":["2.02","9.01"],"status":"ready","headline":"CorMedix Q1 net revenue $127.4M, net income $38.6M; raises FY guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q1 net revenue $127.4M, net income $38.6M, adjusted EBITDA $70.0M; EPS $0.48 basic/$0.43 diluted.","DefenCath revenue $97.5M (incl. $9.0M favorable estimate change); Melinta portfolio $29.9M.","Raises FY2026 guidance: net revenue $325-345M, adjusted EBITDA $115-135M.","Positive Phase III topline for REZZAYO prophylaxis; sNDA submission H2 2026, potential launch 2027.","Cash and investments $178.1M; TPN study trending to 2028, actions to accelerate enrollment."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":659780389.5319148,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":92687,"accession_number":"0001213900-26-047748","cik":1410098,"company_name":"CorMedix Inc.","ticker":"CRMD","form_type":"8-K","filed_at":"2026-04-27T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"CorMedix reports positive Phase III ReSPECT results for REZZAYO in fungal prophylaxis","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Primary endpoint met: fungal-free survival at Day 90 was 60.7% for rezafungin vs 59.0% for standard regimen.","Rezafungin showed favorable safety profile with fewer toxicity-related discontinuations and drug-drug interactions.","Target supplemental NDA submission to FDA in 2H26 based on ReSPECT results.","CorMedix estimates US prophylaxis market opportunity for REZZAYO exceeds $2 billion.","Mundipharma sponsored the trial; holds ex-US rights; Melinta (CorMedix sub) distributes in US."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.9,"calibrated_materiality_score":0.9,"market_cap_usd":659780389.5319148,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":103718,"accession_number":"0001213900-26-024777","cik":1410098,"company_name":"CorMedix Inc.","ticker":"CRMD","form_type":"8-K","filed_at":"2026-03-06T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"CorMedix reaffirms FY2027 DefenCath guidance $100M-$140M; FY2026 revenue guidance $300M-$320M","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Reaffirms FY2027 DefenCath sales $100M-$140M, correcting inadvertent $100M-$125M range from March 5 earnings call.","FY2026 guidance: revenue $300M-$320M, adjusted EBITDA $100M-$125M, DefenCath sales $150M-$170M.","Q4 2025 net revenue $129M, DefenCath sales $91M; FY2025 pro forma net revenue $401M.","Pipeline milestones: REZZAYO prophylaxis Ph3 data expected Q2 2026; DefenCath TPN (NUTRI-LOCK) data 1H 2027.","Balance sheet at Dec 31 2025: cash & short-term investments $149M, convertible debt $150M, shares outstanding 79.1M."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":659780389.5319148,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":103717,"accession_number":"0001213900-26-023881","cik":1410098,"company_name":"CorMedix Inc.","ticker":"CRMD","form_type":"8-K","filed_at":"2026-03-05T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"CorMedix Q4 rev $128.6M; FY2025 net income $163M; reiterates 2026 guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 net revenue $128.6M ($91.2M DefenCath, $37.4M Melinta); net income $14.0M vs $13.5M YoY.","FY2025 total revenue $311.7M, pro forma $401.3M; net income $163.0M ($2.04 diluted EPS) vs prior year loss.","Q4 adjusted EBITDA $77.2M; 2026 guidance: revenue $300-320M, adj. EBITDA $100-125M.","Board approved $75M share repurchase program; cash and short-term investments $148.5M.","Phase 3 Rezzayo ReSPECT data expected Q2 2026; TPN catheter lock study target completion H1 2027."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":659780389.5319148,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":103716,"accession_number":"0001213900-26-002350","cik":1410098,"company_name":"CorMedix Inc.","ticker":"CRMD","form_type":"8-K","filed_at":"2026-01-08T23:59:59+00:00","items":["2.02","5.02","8.01","9.01"],"status":"ready","headline":"CorMedix preliminary Q4 revenue ~$127M, FY2025 pro forma ~$400M; CEO becomes Chairman, new CCO appointed","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 2025 unaudited net revenue ~$127M; FY2025 pro forma net rev. ~$400M (incl. Melinta).","Q4 adjusted EBITDA guidance $77-81M; cash & short-term investments ~$148M.","FY2026 revenue guidance $300-320M; DefenCath rev. $150-170M; adj. EBITDA $100-125M.","CEO Todisco salary raised to $750k (from $665k); target bonus to 75% (from 65%); assumes Chairman role.","Appoints Mike Seckler as EVP & CCO; Phase 3 ReSPECT data expected Q2 2026; Analyst Day Feb 10."],"consensus_eps_estimate":0.8325,"consensus_eps_actual":2.04,"consensus_revenue_estimate":null,"consensus_revenue_actual":311709000.0,"consensus_period":"2025-FY","consensus_source":"xbrl+finnhub","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":659780389.5319148,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":119976,"accession_number":"0001213900-25-108716","cik":1410098,"company_name":"CorMedix Inc.","ticker":"CRMD","form_type":"8-K","filed_at":"2025-11-12T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"CorMedix reports Q3 net income of $108.6M, raises FY 2025 pro forma revenue guidance to $390-410M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net revenue of $104.3M (pro forma $130.8M) driven by DefenCath sales of $88.8M; diluted EPS $1.26.","FY 2025 pro forma net revenue guidance raised to $390-410M; Q4 guidance $115-135M; adjusted EBITDA guidance $220-240M.","One-time $59.7M tax benefit from NOL carryforwards realization contributed to net income.","Melinta acquisition closed Aug 29; integration ahead of schedule with ~$30M annual synergy run-rate expected by end 2025.","Cash and short-term investments $55.7M at Sept 30; projecting year-end ~$100M; Phase III ReSPECT enrollment completed."],"consensus_eps_estimate":0.6581,"consensus_eps_actual":1.97,"consensus_revenue_estimate":null,"consensus_revenue_actual":183093736.0,"consensus_period":"2025-Q3","consensus_source":"xbrl+finnhub","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":659780389.5319148,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":119975,"accession_number":"0001213900-25-100156","cik":1410098,"company_name":"CorMedix Inc.","ticker":"CRMD","form_type":"8-K","filed_at":"2025-10-20T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"CorMedix Q3 prelim rev >$100M, raises FY25 pro forma guidance to at least $375M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q3 2025 preliminary net revenue >$100M; DefenCath revenue >$85M; pro forma net revenue >$125M.","FY25 pro forma net revenue guidance raised from $325-350M to at least $375M.","Q3 adjusted EBITDA expected at least $70M; ~$30M cost synergies on run-rate basis by year-end.","Phase III ReSPECT study of Rezzayo fully enrolled; data expected 2Q 2026.","Cash and equivalents ~$56M at Sep 30; projected year-end cash ~$100M."],"consensus_eps_estimate":0.6581,"consensus_eps_actual":1.97,"consensus_revenue_estimate":null,"consensus_revenue_actual":183093736.0,"consensus_period":"2025-Q3","consensus_source":"xbrl+finnhub","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":659780389.5319148,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":136546,"accession_number":"0001213900-25-093983","cik":1410098,"company_name":"CorMedix Inc.","ticker":"CRMD","form_type":"8-K/A","filed_at":"2025-09-30T23:59:59+00:00","items":["9.01"],"status":"ready","headline":"CorMedix files Melinta acquisition financials; Melinta 2024 revenue $120M, net loss $4.7M","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Melinta 2024 total revenue $119.97M (product $106.3M) vs $105.6M in 2023; net loss narrowed to $4.7M from $36.0M.","Cash and equivalents $49.8M at Dec 31, 2024; total assets $177.6M, notes payable $84.9M.","CorMedix acquired Melinta on Aug 29, 2025 for undisclosed terms; Melinta markets seven anti-infective brands including BAXDELA, VABOMERE, ORBACTIV."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":659780389.5319148,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":136549,"accession_number":"0001213900-25-082956","cik":1410098,"company_name":"CorMedix Inc.","ticker":"CRMD","form_type":"8-K","filed_at":"2025-09-02T23:59:59+00:00","items":["1.01","2.01","3.02","5.02","7.01","9.01"],"status":"ready","headline":"CorMedix completes $300M acquisition of Melinta; raises FY2025 revenue guidance","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Acquisition closed Aug 29, 2025; $260M cash + $40M equity upfront, plus up to $25M in milestone payments.","Pro forma 2025 revenue guidance raised to $325-350M; synergies expected $35-45M annually.","Transaction expected near-term accretive to EPS with double-digit accretion in 2026.","Susan Blum appointed CFO, Elizabeth Hurlburt COO, Matthew David CBO effective immediately.","Contingent payments include tiered royalties on REZZAYO US net sales and low-single-digit royalties on MINOCIN US net sales."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":659780389.5319148,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":136548,"accession_number":"0001213900-25-075010","cik":1410098,"company_name":"CorMedix Inc.","ticker":"CRMD","form_type":"8-K","filed_at":"2025-08-12T23:59:59+00:00","items":["1.01","3.02","9.01"],"status":"ready","headline":"CorMedix closes $150M convertible note offering due 2030 at 4.00% interest","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Issued $150M aggregate principal of 4.00% Convertible Senior Notes due 2030 in a private placement.","Initial conversion rate: 74.2515 shares per $1,000 principal (implied conversion price ~$13.47/share).","Notes issued under indenture with U.S. Bank Trust Company; proceeds not specified but likely for corporate purposes.","Sale exempt from registration under Section 4(a)(2) of the Securities Act."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":659780389.5319148,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":136547,"accession_number":"0001213900-25-072814","cik":1410098,"company_name":"CorMedix Inc.","ticker":"CRMD","form_type":"8-K","filed_at":"2025-08-07T23:59:59+00:00","items":["1.01","2.02","3.02","7.01","8.01","9.01"],"status":"ready","headline":"CorMedix to acquire Melinta for $300M; Q2 revenue $39.7M, net income $19.8M","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Enters agreement to acquire Melinta for $260M cash + $40M stock, plus contingent milestone payments up to $25M and tiered royalties on REZZAYO and MINOCIN.","Acquisition funded by existing cash and $150M convertible notes at 4.00% due 2030; expects closing in September 2025.","Q2 2025 net revenue $39.7M (vs $0.8M YoY); net income $19.8M ($0.29 EPS) vs net loss $14.2M in Q2 2024.","Adjusted EBITDA Q2 2025 $22.4M; operating expenses $18.3M up 18% YoY driven by G&A and R&D.","Contingent payments up to $25M if FDA approves REZZAYO for prophylaxis in stem cell transplant by June 2029."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":659780389.5319148,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":153735,"accession_number":"0001213900-25-059702","cik":1410098,"company_name":"CorMedix Inc.","ticker":"CRMD","form_type":"8-K","filed_at":"2025-06-30T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"CorMedix closes $85M public offering of common stock, net proceeds $82.2M","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Closed public offering of 6,604,507 shares at gross proceeds ~$85M.","Net proceeds ~$82.2M; could reach ~$94.8M if underwriters' option exercised in full.","Underwriters have a 30-day option to purchase up to 990,676 additional shares.","Proceeds to be used for general corporate purposes, including R&D and strategic transactions.","RBC Capital Markets acted as sole bookrunner; Truist, Citizens, Needham as advisors."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":659780389.5319148,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":153734,"accession_number":"0001213900-25-057451","cik":1410098,"company_name":"CorMedix Inc.","ticker":"CRMD","form_type":"8-K","filed_at":"2025-06-25T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"CorMedix shareholders elect all 7 director nominees, approve say-on-pay and auditor ratification","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Directors elected: Dillione 15.6M votes, Duncan 17.6M, Dunton 17.0M, Kaplan 14.2M, Lefkowitz 17.4M, Stewart 15.8M, Todisco 18.3M.","Non-binding say-on-pay passed: 16,086,287 for, 1,999,311 against, 360,596 abstain; 27.6M broker non-votes.","Ratification of CBIZ CPAs as auditor for FY2025 approved: 45,476,764 for, 412,102 against, 156,463 abstain."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.15,"market_cap_usd":659780389.5319148,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":153733,"accession_number":"0001213900-25-056415","cik":1410098,"company_name":"CorMedix Inc.","ticker":"CRMD","form_type":"8-K","filed_at":"2025-06-23T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"CorMedix raises Q2 net sales guidance to $35-40M; LDO customer implements DefenCath with 50%+ more patients","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["LDO customer commenced ordering DefenCath; implementation targets at least 50% more patients than previously communicated.","CorMedix amended existing agreement with LDO customer to reflect anticipated increased product use.","Q2 2025 net sales guidance raised from $31M to $35-40M; modest revenue contribution expected in June with growth through H2 2025.","CEO cites implementation will provide DefenCath access to thousands of adult patients at risk for catheter-related bloodstream infections."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":659780389.5319148,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":153732,"accession_number":"0001213900-25-039903","cik":1410098,"company_name":"CorMedix Inc.","ticker":"CRMD","form_type":"8-K","filed_at":"2025-05-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"CorMedix Q1 2025 net revenue $39.1M, net income $20.6M vs loss; raises H1 guidance to high-end","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q1 net revenue $39.1M; net income $20.6M ($0.32 EPS) vs net loss of $14.5M ($0.25 loss) in Q1 2024.","Adjusted EBITDA $23.6M; cash from operations $19.7M; cash and short-term investments $77.5M at March 31.","Expects to be at high-end of H1 2025 net sales guidance of $62M-$70M based on current order trends.","Inpatient sales team fully staffed; DefenCath inpatient shipments doubled in last 3 months; Phase 3 TPN-CLABSI study started."],"consensus_eps_estimate":null,"consensus_eps_actual":0.3,"consensus_revenue_estimate":null,"consensus_revenue_actual":39081657.0,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":659780389.5319148,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":153731,"accession_number":"0001213900-25-034219","cik":1410098,"company_name":"CorMedix Inc.","ticker":"CRMD","form_type":"8-K","filed_at":"2025-04-22T23:59:59+00:00","items":["4.01","9.01"],"status":"ready","headline":"CorMedix engages CBIZ CPAs as new auditor; Marcum resigns after acquisition","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Marcum LLP resigned April 17, 2025; CBIZ CPAs engaged immediately for FY2025, approved by Audit Committee.","No disagreements or reportable events between CorMedix and Marcum during 2023-2024 or through resignation date.","CBIZ CPAs acquired Marcum's attest business effective November 1, 2024; prior auditor continued until April 17, 2025.","Marcum's reports for 2023 and 2024 contained no adverse opinions or modifications."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":659780389.5319148,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":153730,"accession_number":"0001213900-25-029629","cik":1410098,"company_name":"CorMedix Inc.","ticker":"CRMD","form_type":"8-K","filed_at":"2025-04-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"CorMedix Q1 prelim revenue $39.0M, raises H1 2025 net sales guidance to $62-$70M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Preliminary unaudited Q1 2025 net revenue of $39.0M; expects adjusted EBITDA above $22.5M.","Raises H1 2025 net sales guidance for existing purchasing customers to $62M-$70M from prior range.","Cash and short-term investments at March 31, 2025: approx. $77.5M.","Phase 3 TPN study of DefenCath enrollment expected to begin late April; peak sales potential $150M-$200M.","Forecasts patient utilization growth in H2 2025; unit shipments expected to exceed H1 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":0.3,"consensus_revenue_estimate":null,"consensus_revenue_actual":39081657.0,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":659780389.5319148,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":172415,"accession_number":"0001013762-25-001844","cik":1410098,"company_name":"CorMedix Inc.","ticker":"CRMD","form_type":"8-K","filed_at":"2025-03-25T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"CorMedix Q4 2024 net revenue $31.2M, first profitable quarter; H1 2025 guidance $50-60M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 2024 net revenue $31.2M; net income $13.5M ($0.22/diluted share); adjusted EBITDA $15.3M.","Full year 2024 net revenue $43.5M; net loss narrowed to $17.9M ($0.30/share) from $46.3M in 2023.","Preliminary H1 2025 revenue guidance $50-60M (Q1 >$33M); cash operating expense guidance $72-78M reaffirmed.","Cash and short-term investments $51.7M at Dec 31, 2024; expects >$75M at Q1 2025 end.","Inpatient sales team with Syneos Health nearly complete; Phase 3 DefenCath TPN study to start Q2 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":659780389.5319148,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":172414,"accession_number":"0001213900-25-001392","cik":1410098,"company_name":"CorMedix Inc.","ticker":"CRMD","form_type":"8-K","filed_at":"2025-01-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"CorMedix reports preliminary Q4 2024 net revenue ~$31M, FY ~$43M; Q4 Adj EBITDA >$12M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 2024 prelim unaudited net revenue ~$31M; FY 2024 ~$43M; Q4 Adj EBITDA >$12M.","Open purchase orders >$25M for Q1 2025 delivery; shipping DefenCath to all three MDO customers.","LDO implementation targeted H1 2025; aims for 4,000 patients in H2 2025.","Expanded inpatient deployment with Syneos Health in Q1 2025; field team reorganized, some roles eliminated.","FY 2025 opex guidance $72-78M (excl non-cash/one-time); cash & investments ~$52M at Dec 31, 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.3,"consensus_revenue_estimate":null,"consensus_revenue_actual":43472170.0,"consensus_period":"2024-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.9,"calibrated_materiality_score":0.9,"market_cap_usd":659780389.5319148,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":189414,"accession_number":"0001213900-24-102170","cik":1410098,"company_name":"CorMedix Inc.","ticker":"CRMD","form_type":"8-K","filed_at":"2024-11-25T23:59:59+00:00","items":["5.02","5.07","9.01"],"status":"ready","headline":"CorMedix shareholders approve stock plan amendment increasing authorized shares; all director nominees elected","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Plan amendment to increase share authorization under 2019 Omnibus Stock Incentive Plan approved with 16.5M FOR, 2.8M AGAINST, 0.8M abstain.","All 7 director nominees elected: Dillione, Duncan, Dunton, Kaplan, Lefkowitz, Stewart, Todisco – each received >15.8M FOR votes.","Non-binding advisory vote on 2023 executive compensation passed (FOR: 17.5M, AGAINST: 2.4M).","Ratification of Marcum LLP as auditor for FY2024 approved with 40.5M FOR, 215K against, 370K abstain."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":659780389.5319148,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":189413,"accession_number":"0001213900-24-091959","cik":1410098,"company_name":"CorMedix Inc.","ticker":"CRMD","form_type":"8-K","filed_at":"2024-10-30T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"CorMedix Q3 net revenue $11.5M; net loss narrows to $2.8M; DefenCath access at 60% of US clinics","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q3 2024 net revenue of $11.5M from DefenCath first full quarter; net loss $2.8M ($0.05/sh) vs $9.7M loss ($0.17/sh) in Q3 2023.","Commercial agreements now cover ~60% of US outpatient dialysis centers; four of top five dialysis providers.","Cash and short-term investments $46.0M as of Sep 30, 2024; sufficient for at least 12 months.","Operating expenses $14.1M, up 34% YoY due to selling, marketing, G&A for launch.","Clinical study protocol for TPN indication amendment to be submitted to FDA by mid-November; study start H1 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.54,"consensus_revenue_estimate":null,"consensus_revenue_actual":12262234.0,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":659780389.5319148,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":205914,"accession_number":"0001213900-24-068589","cik":1410098,"company_name":"CorMedix Inc.","ticker":"CRMD","form_type":"8-K","filed_at":"2024-08-14T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"CorMedix Q2 net loss $14.2M; DefenCath sales $0.8M initial, outpatient QTD $5.2M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q2 net loss $14.2M ($0.25/share) vs $11.3M loss ($0.25/share) a year ago, driven by higher operating expenses.","DefenCath net sales $0.8M for partial quarter since April 15 inpatient launch; outpatient QTD sales $5.2M as of Aug 13.","Operating expenses $15.6M in Q2 (+32% YoY) from commercial launch costs; R&D down 86% post-approval.","Cash and short-term investments $45.6M at June 30, sufficient for at least 12 months.","Submitted TPN study protocol to FDA; patient enrollment expected to begin Q1 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.5,"consensus_revenue_estimate":null,"consensus_revenue_actual":806119.0,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":659780389.5319148,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":222935,"accession_number":"0001213900-24-041026","cik":1410098,"company_name":"CorMedix Inc.","ticker":"CRMD","form_type":"8-K","filed_at":"2024-05-09T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"CorMedix Q1 net loss $14.5M; launches DefenCath; CMS TDAPA effective July 2024","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $14.5M ($0.25/sh) vs $10.6M loss ($0.24/sh) in Q1 2023; operating expenses up 44% to $15.9M.","Cash and short-term investments $58.6M; company believes it can fund operations for at least 12 months.","CMS granted HCPCS code and TDAPA for DefenCath effective July 1, 2024, providing 5 years of additional ESRD reimbursement.","Commercial launch of DefenCath in inpatient setting commenced April 15, 2024; outpatient launch expected July 2024.","Entered 5-year supply contract with ARC Dialysis; FDA meeting on DefenCath in TPN requested, feedback expected Q2 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.25,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":659780389.5319148,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":242424,"accession_number":"0001213900-24-021573","cik":1410098,"company_name":"CorMedix Inc.","ticker":"CRMD","form_type":"8-K","filed_at":"2024-03-12T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"CorMedix reports Q4 2023 net loss $14.8M; FDA approved DefenCath; launch April 2024","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss Q4 2023 $14.8M ($0.26/sh) vs $8.2M ($0.20/sh) Q4 2022; operating expenses $15.7M.","Full year 2023 net loss $46.3M ($0.91/sh) vs $29.7M ($0.74/sh) in 2022.","FDA approved DefenCath Nov 15, 2023; commercial launch in inpatient setting planned April 15, 2024.","CMS TDAPA application under review; targeting July 1, 2024 outpatient launch.","Cash and short-term investments $76.0M at Dec 31, 2023; sufficient for at least 12 months."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":659780389.5319148,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}